Curatis Holding AG (FRA:26U)

Germany · Delayed Price · Currency is EUR

17.80

-0.20 (-1.11%)

Last updated: Oct 23, 2026, 8:07 AM CEST

Market Cap	100.37M +46.7%
Revenue (ttm)	14.62M +32.8%
Net Income	-712.81K
EPS	-0.14
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	500
Open	17.80
Previous Close	18.00
Day's Range	17.80 - 17.80
52-Week Range	11.70 - 28.60
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Dec 22, 2026

About Curatis Holding AG

Curatis Holding AG engages in the acquisition, development, and commercialization of medicines for the prevention, diagnosis, and treatment of rare and specialty care diseases. It offers its products in the areas of fentanyl, breakthrough pain, antiplatelet, metastatic hormone receptor-positive breast cancer, anti-arrhythmic, nasal oil, wilson’s disease, cyanide poisoning, digoxin toxicity, antihypotensive, bladder pain syndrome/intersticial cystitis, antibioticum, diagnostic ophthalmology, antiviral, ophtalmic/ antibioticum, gentamycin collage... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 2002

Employees 9

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol 26U

Financial Performance

In 2025, Curatis Holding AG's revenue was 10.80 million, an increase of 56.61% compared to the previous year's 6.90 million. Losses were -1.42 million, -67.41% less than in 2024.

Financial numbers in CHF Financial Statements